肿瘤无缝2/3期试验设计:灵活样本量确定
针对传统固定样本量无缝2/3期设计在疗效数据有限时假设不准的问题,提出基于治疗效应分布设计、并在2期部分根据观察效应动态确定3期分析样本量的新方法。该设计可减少样本量和/或提高把握度,适用于加速开发策略。
要点
- 传统固定样本量设计在疗效数据有限时易因假设不准影响试验。
- 新设计在2期部分根据观察到的治疗效应动态确定3期样本量。
- 相比传统设计,可减少样本量和/或提高把握度。
核心结论
- 基于治疗效应分布并动态确定3期样本量的无缝2/3期设计,相比固定样本量设计可减少样本量和/或提高把握度。
研究设计与样本
- 方法学研究,提出肿瘤无缝2/3期试验的灵活样本量确定设计,3期分析样本量不预先设定而依据2期观察效应动态确定。
主要发现
- 新设计在2期部分根据观察到的治疗效应动态确定3期分析样本量。
- 相比传统固定样本量无缝2/3期设计,可减少样本量和/或提高把握度。
临床怎么用
- 适用于采用激进开发策略、希望加速有效治疗交付的肿瘤药物研发项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conventional seamless phase 2/3 design with fixed sample size determination (SSD) has gained its popularity in oncology drug development due to attractive features such as significantly shortening the development timeline, minimizing sample size, as well as early decision making. However, this design is not immune to inaccurate treatment effect assumption when only limited efficacy data are available at study design stage. We propose an innovative seamless phase 2/3 study design with flexible SSD for oncology trials, in which the trial is designed under a distribution of treatment effect instead of one single assumption due to huge uncertainty of treatment effect at design stage and the sample size for end of phase 3 analysis is not predetermined at design stage, but rather dynamically determined based on observed treatment effect at phase 2 portion. Some practical sample size determination rules for end of phase 3 analysis will be discussed. The proposed design can lead to reduced sample size or/and improved power compared with conventional seamless phase 2/3 design with fixed SSD. This innovative study design can be especially useful for programs with aggressive development strategy to expedite the process in delivering efficacious treatment to patients.
引用
- Teng Z, Tian Y, Liu Y, et al. Seamless phase 2/3 oncology trial design with flexible sample size determination. Stat Med. 2020. PMID: 32338410. doi:10.1002/sim.8543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。